Effects of overweight/obesity and type 2 diabetes mellitus on leptin and visfatin levels
SUN Xia1, ZHU Yan2, ZHENG Peng1, XU Aihua2, DONG Haina3
1. Department of Endocrinology, Lishui TCM Hospital Affiliated to Zhejiang Chinese Medical University, Lishui, Zhejiang 323000, China; 2. Lishui Municipal Central Hospital, Lishui, Zhejiang 323000, China; 3. Lishui University, Lishui, Zhejiang 323000, China
Abstract：Objective To investigate the effects of the link between overweight/obesity and type 2 diabetes mellitus (T2DM) on leptin and visfatin levels. Methods Males without T2DM and male patients with T2DM hospitalized in Lishui Municipal Central Hospital from January to June, 2017 were enrolled. Subjects' age and medical history of diseases were collected. The height and body weight were measured, and the body mass index (BMI) was estimated. The leptin and visfatin levels were determined, and compared between patients with and without T2DM, and between patients with and without overweight/obesity. The effect of the link between overweight/obesity and T2DM on leptin and visfatin levels was examined using a generalized linear regression model. Results There were 66 patients with T2DM, with a mean age of (49.70±9.45) years and a mean diabetes duration of (4.99±4.46) years, and there were 64 patients without T2DM, with a mean age of (43.89±0.20) years. The leptin [ (3.17±0.36) vs. (3.03±0.30) ng/mL; t=2.387, P=0.018] and visfatin levels [ (29.14±3.16) vs. (21.81±3.32) ng/mL; t=12.900, P<0.001] were significantly greater in T2DM patients than in patients without T2DM. The leptin level was significantly greater in patients with overweight/obesity than in those without overweight/obesity [ (3.27±0.32) vs. (2.92±0.26) ng/mL; t=6.634, P<0.001], and the visfatin level was significantly lower in patients with overweight/obesity than in those without overweight/obesity [(24.38±5.14) vs. (26.71±4.36) ng/mL; t=2.780, P=0.006]. Generalized linear regression analysis showed interacting effects of overweight/obesity and T2DM on leptin (β=0.286, P=0.003) and visfatin levels (β=2.709, P=0.008). Conclusion The interaction between overweight/obesity and T2DM affects leptin and visfatin levels.
[1] ANDRADE-OLIVEIRA V,CAMARA N O,MORAES-VIEIRA P M.Adipokines as drug targets in diabetes and underlying disturbances[J/OL].J Diabetes Res,2015[2022-03-27].https://doi.org/10.1155/2015/681612. [2] 迪娜·木合亚提,吕梅霞,木海热姆·杰力力,等.维吾尔族居民脂肪细胞相关因子与超重、肥胖的关联分析[J].预防医学,2021,33(7):704-706. [3] 荣灿,胡云.瘦素抵抗与糖尿病相关研究进展[J].实用老年医学,2021,35(10):1008-1011. RONG C,HU Y.Research progress of leptin resistance and diabetes[J].Pract Geriatr,2021,35(10):1008-1011. [4] 朱俊瑶,郑佳琦,黄慧君,等.高脂饮食引起小鼠皮下脂肪组织形态和功能异常的机制研究[J].预防医学,2019,31(12):1254-1257. ZHU J Y,ZHENG J Q,HUANG H J,et al.Mechanism of morphological and functional abnormalities of subcutaneous adipose tissues in mice induced by high-fat diet[J].Prev Med,2019,31(12):1254-1257. [5] FRANCO-TREPAT E,GUILLÁN-FRESCO M,ALONSO-PÉrEZ A,et al.Visfatin connection:present and future in osteoarthritis and osteoporosis[J/OL].J Clin Med,2019,8(8)[2022-03-27].https://doi.org/10.3390/jcm8081178. [6] DAKROUB A,A NASSER S,YOUNIS N,et al.Visfatin:a possible role in cardiovasculo-metabolic disorders[J/OL].Cells,2020,9(11)[2022-03-27].https://doi.org/10.3390/cells9112444. [7] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67. Chinese Diabetes Society.Guidelines for the prevention and controlof type 2 diabetes in China (2017 editon)[J].Chin J Diabetes Mellit,2018,10(1):4-67. [8] GARVEY W T,MECHANICK J I,BRETT E M,et al.American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity[J].Endocr Pract,2016,22(Suppl.3):842-884. [9] 穆倩,张志国,张翼飞.瘦素抵抗相关机制的研究进展[J].中华内分泌代谢杂志,2020,36(6):515-519. MU Q,ZHANG Z G,ZHANG Y F.Research progress of leptin resistance mechanism[J].Chin J Endocrinol Metab,2020,36(6):515-519. [10] PENG J,YIN L,WANG X.Central and peripheral leptin resistance in obesity and improvements of exercise[J/OL].Horm Behav,2021,133[2022-03-27].https://doi.org/10.1016/j.yhbeh.2021.105006. [11] MOONISHAA T M,NANDA S K,SHAMRAJ M,et al.Evaluation of leptin as a marker of insulin resistance in type 2 diabetes mellitus[J].Int J Appl Basic Med Res,2017,7(3):176-180. [12] KHAN Z,KHAN A,GHAFFAR T,et al.Correlation between serum leptin level and Body mass index(BMI)in patients with type 2 diabetes Mellitus[J].J Pak Med Assoc,2020,70(1):3-6. [13] 龚琳捷,张松.内脂素在代谢性疾病中的研究进展[J].中国临床研究,2021,34(10):1409-1412. GONG L J,ZHANG S.Research progress of visfatin in metabolic diseases[J].Chin J Clin Res,2021,34(10):1409-1412. [14] MATTU H S,RANDEVA H S.Role of adipokines in cardiovascular disease[J].J Endocrinol,2013,216(1):17-36. [15] TAŞKESEN D,KIREL B,US T.Serum visfatin levels,adiposity and glucose metabolism in obese adolescents[J].J Clin Res Pediatr Endocrinol,2012,4(2):76-81. [16] CHEN M P,CHUNG F M,CHANG D M,et al.Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2006,91(1):295-299. [17] PAGANO C,PILON C,OLIVIERI M,et al.Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans[J].J Clin Endocrinol Metab,2006,91(8):3165-3170. [18] KRALISCH S,KLEIN J,LOSSNER U,et al.Isoproterenol,TNFalpha,and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytess[J].Mol Cell Endocrinol,2005,240(1/2):43-49. [19] 赵冉,韩辉,于春晓,等.绝经后2型糖尿病患者性激素水平和血脂及内脏脂肪面积的关系[J].中华内分泌代谢杂志,2019,35(11):950-954. ZHAO R,HAN H,YU C X,et al.Relationship between sex hormones, lipids and visceral fat area in postmenopausal women with type 2 diabetes mellitus[J].Chin J Endocrinol Metab,2019,35(11):950-954.
